The current outbreak of a new strain of E.coli in Germany could see interest grow for PYCs antimicrobial program.
Currently PYC are working with Medimmune(AstraZeneca),scanning PYCs libraries for peptides useful in controling gram negative bacterium, Pseudomonas aeruginosa.PYC also have an inhouse program targeting Acinetobacter baumanii. Both are superbugs responsible for significant numbers of hospital-based infections.
AstraZeneca are one of only a few pharmas with solid R&D into the Antimicrobial,Antibacterial,Antibiotic field.
The following link is a Reuters article on the outbreak. Cheers ST http://www.guardian.co.uk/uk/2011/may/30/ecoli-outbreak-death-toll
PYC Price at posting:
6.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)